HHS, VA partner on psychedelic mental health treatments

The U.S. departments of Health and Human Services (HHS) and Veterans Affairs (VA) have entered into a five‐year agreement to coordinate research, clinical development and future implementation of rapid‐acting psychiatric treatments, including psychedelic‐based therapies, for veterans with serious mental health conditions, an HHS news release stated. Under the agreement, the agencies will expand clinical research participation, support workforce training, develop clinical protocols and collect real‐world evidence to help prepare the VA health care system for potential future Food and Drug Administration–approved treatments. The initiative is part of the Trump administration's broader effort to accelerate development of treatments for serious mental illness and substance use disorders. The agreement remains in force for five years, with the option to renew.

Authors

Publication Details

Journal
Mental Health Weekly
Published
2026-07-17
DOI
https://doi.org/10.1002/mhw.34944
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HHS, VA partner on psychedelic mental health treatments

Valerie A. Canady
Mental Health Weekly
Psychedelics and Drug Studies
article

HHS, VA partner on psychedelic mental health treatments

Valerie A. Canady
article en

Abstract

The U.S. departments of Health and Human Services (HHS) and Veterans Affairs (VA) have entered into a five‐year agreement to coordinate research, clinical development and future implementation of rapid‐acting psychiatric treatments, including psychedelic‐based therapies, for veterans with serious mental health conditions, an HHS news release stated. Under the agreement, the agencies will expand clinical research participation, support workforce training, develop clinical protocols and collect real‐world evidence to help prepare the VA health care system for potential future Food and Drug Administration–approved treatments. The initiative is part of the Trump administration's broader effort to accelerate development of treatments for serious mental illness and substance use disorders. The agreement remains in force for five years, with the option to renew.

Mental Health WeeklyVol. 36(28)
Good health and well-being
Openalex Percentile: Top 5%
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.